← board
TRLV
distress 2/10 · well-funded / low risk$8.70+0%today-33% from 52w high
Revenue
$287M
Liquidity
$353M
Runway
—
Shares 1y
—
Price & events
+7.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
+3.4%
1W
+2.0%
1M
+14.3%
3M
+1.3%
6M
+95.9%
1Y
-20.7%
2Y
-73.2%
5Y
-74.0%
All
Overview
- Volume
- 65.13K
- 52 Week Range
- $4.06 – $13.00
- Float Shares
- 167.61M
- Short %
- 0.49%
- % Held by Insiders
- 1.34%
- % Held by Institutions
- 6.33%
- RVOL
- 0.04x
- Beta
- 1.66
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-07earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $19 (+124% upside) · 5 analysts
- 2026-07-20Cantor FitzgeraldOverweight
Competitors
- none identified
Recent news
- 2026-07-20TRLV Initiated by Cantor Fitzgerald -- Rating Set to Overweight - GuruFocus
- 2026-07-13Why Is Trulieve (NYSE:TRLV) Expanding Its NYSE Presence? - Kalkine Media
- 2026-07-08AdvisorShares Trust reports 10.64M TRLV shares (NYSE: TRLV) ownership - Stock Titan
- 2026-07-03Is Trulieve (TRLV) Quietly Redefining Its Capital Discipline With Georgia Expansion And Finance Restructuring? - simplywall.st
- 2026-06-26Enterprise value to revenue forward of Trulieve Cannabis Corp. Subordinate Voting Shares – NYSE:TRLV - TradingView
- 2026-06-26Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan - coalvalleynews.com
- 2026-06-26Trulieve Cannabis CEO Kim Rivers sells $1.2m in shares - Investing.com
- 2026-06-25Trulieve Cannabis CEO Kim Rivers sells $8.9 million in stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.